AbbVie steps into the obesity drug race, licensing medicine from Danish firm

The obesity medicine field has gained a new entrant, with AbbVie on Monday announcing it had licensed an experimental weight loss drug from a Danish company that is in a Phase 1 trial.

The deal includes a $350 million upfront payment to the company, Gubra, for the rights to its drug, called for now GUB014295. AbbVie will pay up to some $1.9 billion if certain development and sales milestones are met.

The agreement comes less than a year since Robert Michael took over as CEO of AbbVie and as the company looks for its next top-selling drugs following the loss of patent protection for its mega blockbuster autoimmune treatment Humira. In a statement, Michael said that the Gubra partnership offers “a compelling opportunity based on the potential to address patient needs while also fostering long-term growth for our company.”

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Democrats float extending enhanced Affordable Care Act subsidies in year-end deal

Chief Washington Correspondent Rachel Cohrs Zhang reports on the intersection of health policy and business in Washington. She covers Capitol Hill, lobbying, and federal agencies.

December 6, 2024

Wegovy study details revive debate over GLP-1 impact on devices

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. More complete data from a clinical trial

November 13, 2023

Same-sex sexual behavior may be a common feature of primate reproduction, study suggests

Observations of a wild colony of macaques over three years show same-sex sexual behavior among males is widespread and may be beneficial.

July 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.